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KRAS Mutation in Patients Undergoing Hepatic Resection for
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Patients with colorectal cancer (CRC) have experienced remarkable progress in a range of surgical and oncologic manage-
ment strategies over the past decades, with a corresponding improvement in survival.1 As a consequence, the course of dis-
ease has changed both in terms of recurrence patterns and long-term outcomes, as evidenced from national cohort
studies.2,3 The majority of patients with CRC will develop disease recurrence within the first 2 years, and >50% of these
individuals will develop a single-organ recurrence, of whom less than one-third will be offered metastatic surgery. The liver
is the most frequent site of disease recurrence. As resectability criteria have changed over the past 20 years, with changes in
preoperative techniques (eg, the use of forced liver hypertrophy and staged resection procedures) noted among others,4 it
has both increased the number of surgical resections and also improved outcomes. Indeed, improvements in patient selec-
tion and surgical techniques have resulted in improved outcomes after hepatic resection for patients with a colorectal liver
metastasis (CRLM), with 5-year and 10-year overall survival rates reported to be as high as 40% and 20%, respectivley.5
However, the selection of operability and resectability remains a controversial topic and continues to be based largely on
subjective judgment with considerable variation noted among clinicians, even those deemed to be leading experts in the
field.6 Furthermore, metastasis detection and patient selection have improved with better imaging modalities, including
contrast-enhanced ultrasonography, computed tomography, and positron emission tomography scanning. However, even
imaging has its limitations, including the problem of “disappearing liver metastasis,” which are increasingly noted after
neoadjuvant chemotherapy.7 Furthermore, the practice of routine perioperative chemotherapy differs between continents
and remains an area of debate, with results from preoperative chemotherapy trials demonstrating only a modest increase
in survival at the subsequent cost of increased surgical morbidity. Even among patients with a complete pathological
response, long-term remission occurs in only 20% to 50% of patients treated with systemic therapy. Consequently, and
despite the many advances, the majority of patients who undergo hepatic resection for CRLMs experience disease recur-
rence and die of the disease. Thus, understanding the underlying biology, both for improved prediction and for defining
new therapeutic targets, becomes important.
CRC progression follows distinct pathways of genetic instability with defined clinical outcomes and associated mo-
lecular features. Proposed clinical-morphological-genetic classifications for classifying patients into distinct prognostic
groups have not replaced TNM staging for prognosis; in patients with primary resectable disease, lymph node status
remains the most prognostic feature, despite its controversial standing. However, some genetic features have appeared as
potential predictive and prognostic factors, including KRAS mutation status. KRAS is an oncogene located downstream of
the epidermal growth factor receptor (EGFR), which is the target for anti-EGFR treatment, such as cetuximab. It is inter-
esting to note that patients with KRAS wild-type status respond best to anti-EGFR treatment. KRAS is known as an early
mutated event in CRC and is found in approximately 15% of patients with advanced adenomas and in 35% to 45% of
patients with primary CRC (TNM stages I-III).8,9 The frequency of KRAS mutations in patients with a CRLM
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corresponds well, but not perfectly, with the status of the
primary tumor. Studies have reported the variably of
KRAS testing in the primary tumor, metastasis, or both,
with some mutations noted on formalin-fixed and others
on fresh frozen tissue. Despite this similarity with regard
to KRAS status, it is clear that primary tumors and their
corresponding CRLMs are genetically different.10 In gen-
eral, KRAS mutations are associated with a more aggres-
sive tumor behavior across the spectrum of CRC
development, from adenomas to primary tumors, and
patients with KRAS mutations have a poorer overall sur-
vival after liver resection.11
In this issue of Cancer,12 investigators from the Me-
morial Sloan-Kettering Cancer Center studied the predic-
tive role of KRAS for patterns of disease recurrence among
patients undergoing hepatic resection for CRLMs in addi-
tion to hepatic artery infusion (HAI) therapy. The study
by Kemeny et al demonstrates that patients with KRAS
mutations have shorter recurrence-free survival and an
increased risk of developing liver and lung metastasis.
These findings12 corroborate previous results demon-
strated in other patient cohorts, including the series from
Johns Hopkins University,13 The University of Texas
MD Anderson Cancer Center,14 and Vienna,15 which all
reported reduced recurrence-free and overall survival for
patients with KRAS mutations. It is thus tempting to sug-
gest KRAS as a strong and independent prognostic factor,
and one that even overrules current clinical risk scores and
other prognostic features in patients undergoing surgery
for liver metastases. However, these cohorts are fairly dif-
ferent in size and patient selection and generalizing may
not be warranted beyond the reported cohorts. One
study14 was based on 193 patients of a series of 1406
patients consecutively treated for CRLMs (14%), whereas
the other studies represented cohorts ranging from 60 to
169 patients, based on several selection criteria as well as
variability in available tissue for DNA extraction and
mutation analysis. Furthermore, the prevalence of KRAS
mutations found in the cohorts ranged from 18% (or
14% if the NRAS mutations were excluded) in The Uni-
versity of Texas MD Anderson Cancer Center series14 to
25% in the Vienna series,15 29% in the Johns Hopkins se-
ries, and 30% in the Memorial Sloan-Kettering Cancer
Center study.12 It is interesting to note that the presence
of the BRAF mutation, a rare but very strong negative pre-
dictor that is reported to occur in 5% to 10% of patients
with CRC,16 was either not found at all15 or was only
present in 0.6%,12 1%,14 and 2%,13, of patients, respec-
tively, which may point to a somewhat preselected popu-
lation of patients. All patients had received some form of
neoadjuvant chemotherapy (with or without bevacizu-
mab); some included concomitant ablation techniques13
and only 1 study included patients who received HAI
therapy only,12 a therapeutic option that is clearly not
widespread in use and very institution-dependent in terms
of the reported benefit and outcomes.
This obvious heterogeneity does not necessarily
devaluate or rule out the prognostic information found
for KRAS in each and every cohort, but it questions the
role of KRAS as a useful prognostic biomarker in an
upfront selection of patients with CRLMs and the pro-
posed relation to prognosis. More importantly, it raises
doubts regarding the role of KRAS in decision-making
prior to surgical resection. For one, we do not know how
information regarding a KRAS mutation would compare
in strictly unselected, all-comer cohorts of patients under-
going hepatic resection. In addition, we do not know
whether the KRAS status also is mirrored in those patients
not undergoing hepatic resection and therefore may
instead be a driver of prognosis not influenced by the
intervention per se. Indeed, one may envision the true
controls to be patients with KRAS wild-type who did not
undergo hepatic resection, and how mutational status cor-
responded with biological disease progression and clinical
outcome for this group. Because distant metastases is what
eventually kills patients, it would be of interest to learn
whether it is KRAS mutation status or undergoing liver
surgery per se that changes the course of the disease.
The presence of the KRAS mutation may simply be a
byproduct of the selection process, both in terms of cancer
biology and disease aggressiveness, as well as clinical crite-
ria and the selection process for various types of treatment
in each and every institution. It begs the response to sev-
eral additional questions that are important in the current
and often difficult decision-making process for patients
with a CRLM. For example, how well does KRAS predict
prognosis for patients who are treated with a liver-first
(without neoadjuvant chemotherapy) approach? The
reported studies included patients who were all given a
neoadjuvant chemotherapy regimen of some sort. What is
the role of KRAS in patients whose CRLMs were removed
with a simple wedge resection, in contrast to those
patients who require formal hepatectomy (ie, representing
either size or the number of tumors in addition to loca-
tion)? It would be of interest to determine whether KRAS
has the same predictive value in patients with single-
metastasis disease compared with that of patients with
multiple CRLMs. Indeed, the multivariable analysis by
Kemeny et al12 demonstrated that having 3 metastases
was an independent prognostic factor for recurrence-free
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survival together with KRAS status in the patient cohort
that received HAI. Furthermore, how does KRAS status
contribute to our understanding of cancer biology and
clinical prediction in synchronous compared with meta-
chronous CRLMs? Would KRAS be influential in the
choice of strategy for a primary versus liver-first approach
or choice of (neo)adjuvant chemotherapy? Does KRAS
play a predictive and prognostic role in such clinical set-
tings? We cannot tell from the current data, but we would
surely like to learn the answers.
The clinical role of KRAS status in patients with re-
sectable CRLMs is definitely not settled. The response to
anti-EGFR therapy among patients with nonresectable
metastatic disease is being explored to further illuminate
the potential response factors, many of which include
downstream genetic signaling of the EGFR pathway.17,18
Plausibly, one would believe that patients with a wild-type
KRAS status (and who therefore are eligible for treatment
with cetuximab) would benefit from adjuvant anti-EGFR
treatment after liver resection for a CRLM. It is interest-
ing to note that the recent EPOC study19 found, in con-
trast to the implied biological response and to the
investigators’ surprise, that patients with the KRAS wild-
type mutation who received cetuximab actually fared
worse than those who did not receive this treatment. If
nothing else, it reveals that cancer biology continues to be
poorly understood.
The frequently used and reported clinical risk scores
for patients with CRLMs who are undergoing hepatic
resection are able to stratify patients into high-risk and
low-risk groups. Similarly, KRAS mutation status may
also point to a certain outcome, whereas neither system
allows for the accurate prediction of the individual patient
in whom a potential cure is clearly precluded. Further-
more, it remains to be demonstrated how KRAS may pre-
dict prognosis and disease behavior when compared with
other and apparently strong predictors of outcome, rang-
ing from alternative mutations, microRNAs, and circulat-
ing tumor cells.
We do agree with the sentiments expressed by Vau-
they and Kopetz20 in a recent editorial published in Can-
cer that under the current multidisciplinary and
multistrategic approach to CRLMs, with several strategies
currently in use for preoperative assessment and presurgi-
cal treatment, the use of clinical risk scores is made unreli-
able or even useless for the comparison of research results
and/or for prognostic purposes. We therefore may have to
turn to the underlying biology to better understand the
metastatic processes; the molecular mechanisms; and
what factors may be of importance for monitoring, prog-
nostication, and even improved targeted therapy. Last, we
may find predictors that would make hepatic surgery fu-
tile and not necessary for some patients, in particular if it
does not alter the disease course or does not provide a
chance for cure. The recent prognostic studies on KRAS11-
15 have demonstrated that both overall and recurrence-
free survival are considerably shortened, and the risk of
distant metastasis in the lungs, brain, and other sites may
be increased. How to use this information intelligibly for
future patient selection is hard to discern because it
depends both on an already present image-based and
clinical-based patient selection and interacts with related
genetic factors and molecular pathways. Whether KRAS is
truly a biomarker for cancer biology or a byproduct of
patient selection therefore remains an open question.
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